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“Atheromatous emboli” is a general description for embo-
lization of any atheromatous material. The term “athero-
emboli” is used to refer to the dislodgement of vascular
plaque material that contains cholesterol crystals plus red
blood cells and fibrin. These can occlude major systemic
vessels and result in organ infarction. “Cholesterol emboli”
consist primarily of release of cholesterol crystals from
ulcerated vascular plaques; the particles are usually smaller in
size and are more widely spread than atheroemboli. The
cholesterol embolization syndrome (CES) was first noted in
an autopsy series by Flory in 1945. This original observation
found vascular occlusions in nine of 267 patients with
advanced aortic atherosclerosis (1). Skin involvement from
CES results in a variety of manifestations, often referred to
as blue-toe syndrome, purple-toe syndrome, or trash foot.
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Obstruction of cutaneous vessels results in the mottled
purple pattern of livedo reticularis. Ulcers, cyanosis, pur-
pura, and gangrene may result from diffuse extremity vas-
cular obstruction. Renal, neurologic, and cutaneous mani-
festations tend to dominate the clinical picture after vascular
interventions such as cardiac catheterization.
Nearly every organ system has shown histologic involve-
ment in autopsy studies (2). These include visual changes
from retinal emboli (3), transient ischemic attacks and
stroke (4,5), gastric (6) and small-bowel bleeding (7), and
renal transplant organ failure (8). Major risk factors for this
syndrome include advanced age (with most patients over 60
years of age), repeat vascular procedures, female gender, and
peripheral vascular disease. The presence of identifiable aortic
atherosclerosis by noninvasive means appears to increase the
risk (9). Minor predictors for CES include the rate of antico-
agulation administration, the use of thrombolytics, elevated
baseline creatinine levels, low platelet counts, longer periods of
anticoagulation, and use of larger catheters (10).
The pathogenesis of CES is thought to rely on the
disruption of vascular plaque with the release of subendo-
thelial cholesterol crystals into the bloodstream. The initial
event may be spontaneous (i.e., due to plaque rupture) (11),
medication-induced (i.e., after using thrombolytics or anti-
coagulation) (12) or, most often, following vascular endo-
thelial trauma (either surgical or percutaneous injury)
(13,14). In addition to the vascular obstruction from the
cholesterol crystals, an inflammatory process is incited,
leading to lymphocytic and mononuclear cell infiltration,
ultimately with fibrosis. The diagnosis of CES relies on
clinical findings in a patient with recent intravascular
instrumentation or evidence of significant vascular disease.
Whereas dermatologic or neurologic impairment may be
seen early, renal involvement is characterized by progressive
worsening of function over a two- to four-week period
beyond the index event. Biopsy specimens are diagnostic
and reveal “ghost” crystals lodged within vascular spaces
(15). Unfortunately, although specific, biopsies may suffer
from a lack of sensitivity depending on the organ studied
and the degree of embolization.
The incidence of CES varies based on population char-
acteristics and diagnostic criteria. Large retrospective studies
of patients undergoing intravascular procedures have re-
ported a 0.6% to 0.9% incidence (10,16). Autopsy studies
performed on patients after resection of abdominal aortic
aneurysms show evidence of cholesterol emboli in as many
as 77% (17). In a prospective study of CES, Saklayen et al.
(18) evaluated 267 patients undergoing coronary angiogra-
phy and found that no patients had dermatologic findings
but five patients showed creatinine elevations 0.5 mg/dl,
and three 1.0 mg/dl, at three weeks. They concluded the
incidence of CES was 2%.
In the current study by Fukumoto et al. (19), in this issue
of the Journal, the authors report the occurrence of CES in
1.4% of 1,786 patients undergoing left heart catheterization.
This figure seems consistent with the prior prospective
study (18) but is several-fold higher than the retrospective
studies. There are several possible reasons for the discrep-
ancy. “Definite CES,” as defined by the authors, accounted
for only 12 of the 25 cases (0.75% incidence). Although the
dermatologic changes noted are found in CES, they are not
specific and may be noted with arterial thrombosis/
embolization, hypercoagulable states, and severe peripheral
vascular disease. The additional 13 cases of “possible CES”
involved predominantly renal abnormalities. Because an
elevated serum creatinine after cardiac catheterization has a
broad differential diagnosis, other factors may have played at
least a contributing role, especially related to the use of
contrast media (20). As opposed to the progressive nature of
renal failure due to cholesterol emboli, ischemic or direct
nephrotoxic damage from contrast media administration
results in an acute elevation in serum creatinine, usually
peaking at 48 h, with a subsequent return to baseline.
Long-term renal dysfunction due to contrast media is well
described, but it is unusual and more likely to occur after the
use of large volumes of contrast and in diabetic patients who
have an elevation in their baseline creatinine (21). The
pattern of an early creatinine elevation with a subsequent
progressive decline to baseline values adds to the ability to
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discern contrast-related changes in renal function from
cholesterol embolic changes. Factors that predispose pa-
tients to contrast media nephropathy include the type and
amount of contrast dye, the baseline creatinine, the presence
of diabetes mellitus, the use of hydration before the proce-
dures, underlying congestive heart failure, and/or the per-
formance of subsequent invasive procedures (20).
Additional, though unlikely, causes of renal dysfunction
not fully excluded in this report include systemic illness such
as vasculitis or endocarditis, direct nephrotoxins such as
anti-inflammatory medications, allergic interstitial nephritis
due to periprocedural antibiotics, and possible progressive
ischemic nephropathy related to renal artery stenosis. Eo-
sinophilia, while noted in 80% of cases of CES, may also be
seen in systemic vasculitis, acute interstitial nephritis, and
contrast-related hypersensitivity renal failure (18). Biopsy
data, not available in this study, would have been compelling
and significantly strengthened their arguments that the
renal dysfunction they observed was due to cholesterol
emboli.
Even if one accepts the limitations inherent in the
diagnosis of CES-induced renal failure, the authors do
point out a potentially important relationship between
C-reactive protein (CRP) and CES. A 4.6-fold increase in
risk of CES was noted in their patients with an elevated
CRP. This observation is quite consistent with recent data
suggesting CRP as a marker of the “inflamed, unstable”
plaque (22,23). Additional observations supporting this
relationship include the ability of statins to decrease CRP
and atherosclerotic events. Anecdotally, simvastatin has
been reported to improve renal dysfunction caused by CES
(24). The unfortunate paradox is that an elevated CRP may
be a marker for those patients with the greatest need for
intervention as well as those at the greatest risk from the
procedure.
Vascular interventional procedures are increasing in num-
ber, especially in the population that is elderly. Although
possibly overestimating the incidence of clinical CES, the
authors have importantly provided added awareness of this
syndrome. Despite our best efforts, treatment of CES
remains supportive. Besides statins, iloprost (25), pentoxi-
fylline (26), and steroids (27) have all been tried with
limited success. As current medical practice continues to
discourage the continuity of care by stressing rapid discharge
and minimizing follow-up, a higher index of suspicion on
the part of those involved in the care of cardiac catheter-
ization patients may be necessary to diagnose this elusive
syndrome.
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